anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: This study aimed to use machine learning to evaluate the risk factors of seizures and develop a model and nomogram to predict seizures in children with coronavirus disease 2019 (COVID-19).
MATERIAL AND METHODS: A total of 519 children with COVID-19 were assessed to develop predictive models using machine learning algorithms, including extreme gradient boosting (XGBoost), random forest (RF) and logistic regression (LR). The performance of the models was assessed using area under the receiver operating characteristic curve (AUC) values. Importance matrix plot and SHapley Additive exPlanations (SHAP) values were calculated to evaluate feature importance and to show the visualization results. The nomogram and clinical impact curve were used to validate the final model.
RESULTS: Two hundred and seventeen children with COVID-19 had seizures. According to the AUC, the RF model performed the best. Based on the SHAP values, the top three most important variables in the RF model were neutrophil percentage, cough and fever duration. The nomogram and clinical impact curve also verified that the RF model possessed significant predictive value.
CONCLUSIONS: Our research indicates that the RF model demonstrates excellent performance in predicting seizures, and our novel nomogram can facilitate clinical decision-making and potentially offer benefit for clinicians to prevent and treat seizures in children with COVID-19.
Generalized social anxiety disorder (GSAD) is one of the most common psychiatric disorders, and often causes significant distress and dysfunction in affected individuals. Although currently available treatments for GSAD are effective, most individuals have residual symptoms after initial psychosocial or psychopharmacologic intervention. Further treatment is necessary for such individuals, but sufficient research has not been done to guide clinicians on what the safest and most effective next step may be. This study will compare the effectiveness of either combining clonazepam or placebo with sertraline or completely switching to venlafaxine in treating GSAD in individuals who have not responded to treatment with sertraline. This study will also examine predictors of treatment response, including factors such as age at disease onset, duration of illness, comorbidities, and genes that influence serotonin and catecholamine metabolism.

Participants in this double-blind study will first partake in an initial 10-week phase in which they will be treated with sertraline. Participants who do not respond to sertraline treatment will proceed to phase two of the study, in which they will be randomly assigned to one of three treatment groups. One group will receive both sertraline and clonazepam, another group will receive both sertraline and placebo, and the third group will receive only venlafaxine. All treatments will continue for 12 weeks. Sertraline and venlafaxine are both FDA-approved for the treatment of GSAD. Clonazepam is widely used for the treatment of anxiety, but is not FDA-approved for the treatment of GSAD. All participants will attend weekly study visits at Weeks 1, 2, 4, 6, 8, and 10. Participants who continue into phase two will attend weekly study visits at Weeks 11-14, 16, 18, 20, and 22. Symptom remission rates and post-treatment social phobia severity will be assessed at Week 22.
The present invention relates to methods for treating autism spectrum disorders and related symptoms. The present disclosure relates to compositions and methods for treating Autism Spectrum Disorder (ASD) by restoring gut microbiota in ASD patients. These methods may be used for ASD patients with or without persistent digestive tract symptoms. Provided herein are methods for ASD treatment in a subject in need thereof, comprising or consisting essentially of administering to the subject a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation. Also provided herein is a method comprising administering an antibiotic to a human subject, purging the gut of a human subject, and administering a purified fecal microbiota to a human subject. Further provided are the assessment and quantitative characterization of patient symptom improvement following treatment as described herein.
The invention relates to a honeyed pill for treating headache. The honeyed pill is characterized by being prepared from the following raw materials in parts by weight: 30 parts of rhizoma gastrodiae, 120 parts of angelica root, 3 parts of asarum, and 15 parts of herba schizonepetae. The preparation is prepared into pills, tablets, oral liquids and capsules by the tradition preparation process or the modern preparation process, preferably honeyed pills. The selected drugs have the efficiency on expelling pathogenic wind from the body surface, calming endogenous wind to relieve convulsion, and relieving stiffness to relieve pain by functioning together. The organic immune function is enhanced by oral administration, and the preparation has good curative effect on headache caused by various reasons. Proved by clinic application, the invention has the advantages of quick action, obvious curative effect, good tolerance property, low cost, and no toxic or side effect.
INTRODUCTION: Heart failure with preserved ejection fraction (HFpEF) is a prevalent comorbidity among patients with end-stage kidney disease. Although sodium-glucose cotransporter 2 inhibitors are validated in treating heart failure and ameliorating left ventricular hypertrophy among non-dialysis patients, the effects on dialysis patients are unknown. We previously investigated the pharmacokinetics of henagliflozin in patients undergoing haemodialysis (HD) or peritoneal dialysis (PD) and clarified its safety.
METHODS AND ANALYSIS: This multicentre, randomised, double-blind, placebo-controlled trial is being conducted at three hospitals in Shanghai, China. A target of 108 HD or PD patients with HFpEF are randomly allocated to treatment group (henagliflozin 5 mg/day in addition to standard therapy) or control group (placebo with standard therapy) at a ratio of 1:1. All subjects will be followed up for 24 weeks. The primary outcome is change in echocardiography-measured left ventricular mass index. The secondary interests include changes in left atrial volume index, E/e', e' and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Intergroup comparisons of change in echocardiography-related outcomes from baseline to 24 weeks are based on a linear regression model adjusted for baseline values (analysis of covariance), and repeated measure analysis of variance with Bonferroni adjustment is employed for comparison of change in NT-proBNP. Subgroup analyses of the primary and secondary outcomes are conducted to determine whether the effect of henagliflozin varies according to dialysis modality. The χ2 method is used to compare the occurrence of adverse events and severe adverse events.
ETHICS AND DISSEMINATION: This trial has been approved by the Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University (LY2023-127-B). All participants provide written informed consent before screening. The results of the trial will be disclosed completely in international peer-reviewed journals. Both positive and negative results will be reported.
TRIAL REGISTRATION NUMBER: ChiCTR2300073169.
The present invention provides a membrane the conductivity of which is dependent on the presence or absence of an analyte.  The membrane comprises a closely packed array of self-assembling amphiphilic molecules and two ionophore components.  A receptor molecule reactive with the analyte is provided on one of the ionophore components.  The binding of the analyte to the receptor molecule causes a change in the relationship between the ionophore components such that the flow of ion across the membrane is prevented or allowed.  The ionophore components are preferably selected from the group consisting of amphotericin B, gramicidin A monomers and combinations thereof, with gramicidin A monomers being particularly preferred.  The present invention also provides a membrane including receptors directed against the Fc region of antibodies.  These receptors are preferably derived from polyclonal antibodies.  These membranes provide a "generic" surface which will bind antibodies in a manner such that the antigen binding regions of the antibody are not hindered.  The present invention further provides a device adapted for implantation in a mammalian body, the device being characterised in that it is coated with a membrane comprising a closely packed array of self-assembling amphiphilic molecules and receptor molecules.  The receptor molecules being such that the attachment of specific cells to the membrane is enhanced or avoided.  It is particularly preferred that the receptor molecules are directed against fibronectin, vitronectin, endothelial cells, or epithelial cells.  It is further preferred that the membrane coating the device also includes a plurality of ion channels such as gramicidin.
The invention relates to a clostridium butyricum strain used for feeding, and an application thereof. The provided clostridium butyricum B1 CGMCC No. 4845 is a Gram-positive rod. When observed by using an optical microscope, the sizes of the strains are (0.6-1.2)mum*(3.0-7.0)mum; the ends of the strains are round; the middle parts of the strains are slightly bulged; the strains are single or in couples; the strains are short-chained; filamentous thallus with peritrichous is occurred; the strains are movable; the spores are egg-shaped, and are grew decentrically or on the minor ends; the strains form white or cream-colored small-scaled round colonies on an anaerobic agarose plate; the strains grow under an anaerobic condition, with a growth temperature range of 20 DEG C to 60 DEG C, and preferably 30 DEG C to 42 DEG C; the growth hydrogen power range of the strains is pH 2-10, and preferably pH 7.0. Microbial manure prepared with the strains brings no toxin and harm, and is gastric juice resistant and bile salt resistant. The microbial manure provides strong inhibiting effects against various harmful bacteria. Therefore, the strains can be widely applied in poultry and livestock cultivation industries. With the strain, animal disease resistance can be improved. The strain has potential to be applied as a substitution of antibiotics used for feeding.
The invention discloses application of miR-27b-3p in diagnosis of hepatic ischemia reperfusion injury. The significant upregulation of miR-27b-3p in HIRI liver was detected by real-time quantitative PCR (qRT-PCR). Bioinformatics analysis showed that SMAD4 is a target gene for miR-27b-3 p. qRT-PCR experiments show that miR-27b-3p can activate the expression of SMAD 4. After the miR-27b-3p simulant is transferred into a HIRI mouse, the liver injury is aggravated, the expression level of SMAD4 is increased, the Wnt/beta-catenin pathway is inhibited, the apoptosis is increased, the cell proliferation is increased, and the injury of ischemia reperfusion to the liver tissue is aggravated. The results of the miR-27b-3p mimics after being transferred into the anoxic/reoxygenation AML12 liver cells have the same trend with in vivo experiments. Therefore, the invention clarifies the action and mechanism of miR-27b-3p in HIRI, and provides a new target and a new idea for the prevention and treatment of HIRI.
Cystic Fibrosis is an autosomal recessive disorder with an incidence of approximately 1 in 33000 live births. It is due to defects in the CFTR gene, which is located on chromosome 7. Gene Therapy holds the promise of addressing the primary defect in CF by reconstituting the CFTR function in the lung. tgAAVCF, which has been genetically engineered to contain the CFTR gene, has been extremely well tolerated following single and multiple dose administrations to the nose, sinus, and lung. Dose-dependent gene transfer has been demonstrated. Although vector gene expression has not been detected, evidence consistent with biological activity was observed in maxillary sinus study, and statistically significant changes in the FEV1 and IL-8 levels were observed in the recently completed multidose aerosol study. These findings are worthy of further investigation.
The invention discloses a kind of combined-enzyme method and extract the method for total flavones in Fructus Citri Sarcodactylis, comprise the following steps: a. pretreatment of raw material；B. defat；C. enzymolysis；D. high temperature enzyme denaturing；E. extracting at constant temperature；F. extract it is centrifuged.The present invention uses ethanol to be Extraction solvent, and low cost is the most environmentally friendly.The present invention uses combined-enzyme method to extract the flavone in Fructus Citri Sarcodactylis, improves yield, and should send out efficient, nontoxic, reaction condition is gentle, for the offer reference of exploitation further of Fructus Citri Sarcodactylis resource.
There is provided a method in medical imaging. In the method, a target is imaged with a hyperspectral imaging system (302) in order to obtain imaging data. The obtained imaging data is pre-processed by spatial and spectral averaging (304, 306). A number of endmembers to be determined from the pre- processed imaging data is selected. The endmembers are extracted from the preprocessed imaging data based on vertex component analysis (308) on the preprocessed imaging data and the selected number of endmembers, said endmembers defining an extremity of projections of the pre-processed imaging data in a subspace spanned by the endmembers. At least one abundance map is generated (310) of the selected number of endmembers in the pre-processed imaging data using a filter vector algorithm (308) on the extracted endmembers and the imaging data.
Subcutaneous biological drug self-administration training was given by the researcher in two stages, theoretical and practical, face to face. Power point presentation and training brochure were used in theoretical training. The practical training given after the theoretical training was given using the Hybrid simulation method. The Wearable Subcutaneous Injection Hybrid Simulator developed by the researcher was worn by the individuals after being informed about its purpose and function. A medicine pen similar to their own medicine pens (demo pen without medicine), dry cotton, alcohol swab (similar to the ones that come in medicine pen boxes), and a small notepad and pen were left in a clean medicine tray on a clean table. Afterwards, they were expected to apply the subcutaneous application step by step as explained to them. Each application step they made incorrectly was corrected and repeated with the support of the researcher.The training took approximately 40 minutes.
The prevalence of tobacco use in India among men has been reported to be high in most parts (generally exceeding 50%). It's use is more common in rural areas as compared to urban areas. Oral cancer, the main cause of which is tobacco, is common in men in developing countries and the most common cancer among men in India. The five year survival rate for oral and pharyngeal cancers even in premier institute like the Tata Memorial Hospital ranges from a poor 8% (hypo pharynx) to 43% (lower lip). Evidence has shown that cessation is the only intervention with the potential to reduce tobacco related mortality in the short- term and medium- term. An emphasis on prevention of tobacco consumption will, in the short run, only have a limited positive effect on tobacco related morbidity and mortality, as prevention strategies do not affect existing consumers. Workplace tobacco cessation activities in India are still in rudimentary stage.

In the proposed study of one year duration, professional help in the form focus group discussion, one to one counseling and pharmacotherapy will be provided to the employees by a team of doctors and counsellors from Tata Memorial Hospital. Self reporting of tobacco history will be validated with Biochemical test. This will add objectivity to the programme, so that, if successful, it can be replicated as a model to promote tobacco control activities at other workplaces. Naked eye examination of oral cavity of all employees for detection of oral pre-cancers and cancers will be done by doctors from the Tata Memorial Hospital. The employees with lesions may be referred for further management, if required. Nursing staff and Doctors attached to the industry and from the local referral hospital will be invited to participate as trainees during the active intervention sessions.

The long term objective of this initiative is to establish a model workplace tobacco cessation and oral cancer screening programme. It will contribute to the human resource and infrastructure development for tobacco cessation services at the industrial unit and at the local referral hospital. Proposed tobacco cessation services in the chemical industry would be of great help for boosting Anti - Tobacco Activities not only in the particular factory unit but also in the nearby industrial and residential zone.
PROBLEM TO BE SOLVED: To obtain a cosmetic that has the promotion of epidermal cell proliferation and antioxidant action and can suppress ski wrinkling and roughening by adding a plant component as antiarol. SOLUTION: This cosmetic contains at least one selected from antiarol, lyoniresinol, rhododendrol, platyphylonol and their glycosides as an active ingredient. The formulation of this active ingredient is 0.001-10wt.% based on the whole amount of the cosmetic. Antiarol occurs in plants in Betulaceae, Simaroubaceae and Lagminosae; lyoniresinol occurs in Rutaceae, Fagaceae, Lauraceae and Ericaceae; rhododendrol occurs in Ericaceae and Pedaliaceae and platyphylonol occurs in Betulaceae. These essential oils are extracted from these plants with a lower alcohol or the like and separated and purified in a usual manner such as silica gel chromatography. Further, they can be prepared through chemical synthesis, cell culture or genetic recombination technique.
Information related to clinical studies of escitalopram in adolescents is approved for Forest Laboratories, Inc.'s Escitalopram Oxalate Tablets and Oral Solution. However, due to Forest Laboratories, Inc.'s marketing exclusivity rights, this drug product is not labeled with that adolescent clinical studies information.

### Adults 

The efficacy of escitalopram as a treatment for major depressive disorder was established in three, 8 week, placebo-controlled studies conducted in outpatients between 18 and 65 years of age who met DSM-IV criteria for major depressive disorder. The primary outcome in all three studies was change from baseline to endpoint in the Montgomery Asberg Depression Rating Scale (MADRS). 

A fixed-dose study compared 10 mg/day escitalopram and 20 mg/day escitalopram to placebo and 40 mg/day citalopram. The 10 mg/day and 20 mg/day escitalopram treatment groups showed statistically significant greater mean improvement compared to placebo on the MADRS. The 10 mg and 20 mg escitalopram groups were similar on this outcome measure.

In a second fixed-dose study of 10 mg/day escitalopram and placebo, the 10 mg/day escitalopram treatment group showed statistically significant greater mean improvement compared to placebo on the MADRS.

In a flexible-dose study, comparing escitalopram, titrated between 10 and 20 mg/day, to placebo and citalopram, titrated between 20 and 40 mg/day, the escitalopram treatment group showed statistically significant greater mean improvement compared to placebo on the MADRS.

Analyses of the relationship between treatment outcome and age, gender, and race did not suggest any differential responsiveness on the basis of these patient characteristics.

In a longer-term trial, 274 patients meeting (DSM-IV) criteria for major depressive disorder, who had responded during an initial 8 week, open-label treatment phase with escitalopram 10 or 20 mg/day, were randomized to continuation of escitalopram at their same dose, or to placebo, for up to 36 weeks of observation for relapse. Response during the open-label phase was defined by having a decrease of the MADRS total score to ≤ 12. Relapse during the double-blind phase was defined as an increase of the MADRS total score to ≥ 22, or discontinuation due to insufficient clinical response. Patients receiving continued escitalopram experienced a statistically significant longer time to relapse compared to those receiving placebo.
PURPOSE: To obtain a melanogenesis inhibitor containing, as active ingredient, echinomycin. CONSTITUTION: This melanogenesis inhibitor contains, as active ingredient, echinomycin, a kind of quinoxaline-based antibiotic. This inhibitor is prepared by conventional method after addition of desired ingredients other than the echinomycin. The other objective skin cosmetic intended for skin whitening effect can be prepared by incorporating a cosmetic base with 10<-7> -10<-5> wt.% of echinomycin. The echinomycin has been discovered from Streptomyces echinatus, and can be obtained by purification and isolation from a culture extract of Actinomyces with the melanogenesis inhibitory activity in B16 mouse melanoma cells serving as indicator; or the echinomycin to be used may be commercially available. This skin cosmetic can be prepared in the form of cream, milky lotion, face lotion, foundation, pack, lotion, get, solution, stick, etc.
BACKGROUND: High salt intake may play a critical role in the etiology of psoriasis. Yet, evidence on the association of high salt intake with risk of psoriasis is limited.
OBJECTIVE: To estimate the association between frequency of adding salt to foods and risk of psoriasis.
METHODS: We conducted a prospective cohort study of 433,788 participants from the UK Biobank. Hazard ratios (HRs) and their 95 % confidence intervals (CIs) for risk of psoriasis in relation to frequency of adding salt to foods were estimated using multivariable Cox proportional hazards models. We further evaluated the joint association of adding salt to foods and genetic susceptibility with risk of psoriasis. We conducted a mediation analysis to assess how much of the effect of adding salt to foods on risk of psoriasis was mediated through several selected mediators.
RESULTS: During a median of 14.0 years of follow-up, 4279 incident cases of psoriasis were identified. In the multivariable-adjusted model, a higher frequency of adding salt to foods was significantly associated with an increased risk of psoriasis ("always" versus "never/rarely" adding salt to foods, HR = 1.25, 95 % CI: 1.10, 1.41). The observed positive association was generally similar across subgroups. In the joint association analysis, we observed that participants with a high genetic risk (above the second tertile) and the highest frequency of adding salt to foods experienced 149 % higher risk of psoriasis, when compared with participants with a low genetic risk (below the first tertile) and the lowest frequency of adding salt to foods (HR = 2.49, 95 % CI: 2.05, 3.02). Mediation analysis revealed that 1.8 %-3.2 % of the positive association between frequency of adding salt and risk of psoriasis was statistically significantly mediated by obesity and inflammatory biomarkers such as C-reactive protein and systemic immune-inflammation index (all P values < 0.004).
CONCLUSIONS: Our study demonstrated a positive association between frequency of adding salt to foods and risk of psoriasis. The positive association was independent of multiple other risk factors, and may be partially mediated through obesity and inflammation.